Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the potential treatment of LN. Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs. The Company’s head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland. The Company focuses its development efforts globally.
Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate Communications and Investor Relations
Aurinia Pharmaceuticals Inc.
#1203-4464 Markham Street
Victoria, BC V8Z 7X8